The use of nerve and muscle biopsy in the diagnosis of vasculitis: a 5 year retrospective study by Bennett, D L H et al.
The use of nerve and muscle biopsy in the diagnosis
of vasculitis: a 5 year retrospective study
D L H Bennett,
1,2 M Groves,
2 J Blake,
2,4 J L Holton,
2 R H M King,
3 R W Orrell,
3
L Ginsberg,
3 M M Reilly
2
See Editorial Commentary,
p 1307
c Supplementary tables 1–3 are
published online only at http://
jnnp.bmj.com/content/vol79/
issue12
1Wellcome Clinical Scientist
Fellow King’s College and
University College London,
London, UK;
2MRC Centre for
Neuromuscular Diseases,
Department of Molecular
Neurosciences, National
Hospital for Neurology and
Neurosurgery and Institute of
Neurology, London, UK;
3Department of Clinical
Neurosciences, Institute of
Neurology, Hampstead Campus,
University College London and
Royal Free Hospital, London, UK;
4Department of
Neurophysiology, Norfolk and
Norwich University Hospital,
Norwich, UK
Correspondence to:
D L H Bennett, Department of
Neurorestoration, CARD Wolfson
Wing, Hodgkin Building, Guy’s
Campus, King’s College London,
London Bridge, London SE1 1UL,
UK; david.bennett@kcl.ac.uk
Received 4 April 2008
Revised 3 August 2008
Accepted 14 August 2008
Published Online First
26 September 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
jnnp.bmj.com/info/unlocked.dtl
ABSTRACT
Introduction: Peripheral nerve vasculitis is an important
condition which can be diagnostically challenging and is
one of the principal current indications for nerve and
muscle biopsy. Previous studies have suggested that
combined nerve and muscle biopsy (usually of the
superficial peroneal nerve and peroneus brevis muscle)
produces a higher diagnostic yield than nerve biopsy alone
in the investigation of vasculitis.
Objective: To determine whether in our two centres
combined nerve (usually the sural) and muscle (usually
the vastus lateralis) biopsy improved diagnostic yield
compared with nerve biopsy alone.
Methods: We interrogated our database of all nerve
biopsies (usually of the sural nerve) performed at our
institutions over 5 years and identified 53 cases of biopsy
proven peripheral nerve vasculitis. Clinicopathological and
neurophysiological data in these patients were reviewed.
Results: The most common clinical presentation was
with a painful asymmetric axonal polyneuropathy or
mononeuritis multiplex (66% of cases). Nerve biopsy
demonstrated definite vasculitis in 36%, probable
vasculitis in 62% and no vasculitis in 2% of cases. In 24
patients a muscle biopsy (usually the vastus lateralis) was
also performed and vasculitis was demonstrated in 46%
of these (in 13% showing definite and 33% probable
vasculitis). There was only one patient in whom vasculitis
was demonstrated in muscle but not in peripheral nerve.
Conclusion: Combined nerve (usually sural) and vastus
lateralis muscle biopsy did not significantly increase the
diagnostic yield compared with nerve biopsy alone. A
sensible approach to the diagnosis of peripheral nerve
vasculitis is to choose a nerve to biopsy which is clinically
affected and amenable to biopsy. If the sural nerve is
chosen, the data suggest that it is not routinely worth
doing a vastus lateralis biopsy at the same time, whereas
if the superficial peroneal nerve is chosen, it seems
appropriate to do a combined superficial peroneal nerve
and peroneus brevis biopsy. It is still not known if both the
sural and superficial peroneal nerves are involved clinically
which one gives the higher yield if biopsied.
Peripheral nerve vasculitis is a pathological pro-
cess involving infiltration of and injury to the
walls of the vasa nervorum by inflammatory
cells,
12 resulting in secondary ischaemia and
damage to the nerve trunk. The diagnosis is
difficult to make on clinical grounds alone and
usually requires the biopsy of affected tissue prior
to starting treatment. Although peripheral nerve
vasculitis is rare, it remains one of the most
important indications for performing a nerve
biopsy. Peripheral nerve vasculitis can occur
either as part of multisystem disorders such as
polyarteritis nodosa or connective tissue disorders
(termed SVN, systemic vasculitic neuropathy)
13 – 5
or as a disorder restricted to the peripheral
nervous system (termed NSVN, non-systemic
vasculitic neuropathy).
6–8 In both groups, striated
muscle as well as peripheral nerve may show
pathological signs of vasculitis. In 1988, Said and
Lacroix reported that up to 45% of patients with
peripheral nerve vasculitis had demonstrable
evidence of vasculitis in the peroneus brevis
muscle (PBM) but not in the superficial peroneal
nerve (SPN) when both were biopsied.
4 This
group therefore suggested that combined SPN/
PBM biopsy (through a common incision) in
patients with suspected peripheral nerve vasculi-
tis would increase the diagnostic yield, an
approach supported by more recent studies.
19
Based on these studies it has also become accepted
practice in units where the sural nerve is the more
usual nerve biopsied to biopsy the vastus lateralis
muscle as well (using a second incision during the
same procedure) when vasculitis is being consid-
ered.
In order to determine whether combined nerve
(usually sural) and vastus lateralis muscle biopsy
improved diagnostic yield compared with nerve
biopsy alone, we studied more than 50 cases of
pathologically confirmed peripheral nerve vasculi-
tis seen at our two institutions over a 5 year
period.
METHODS
Case identification
We interrogated our databases of all nerve and
muscle biopsies performed at the National Hospital
for Neurology and Neurosurgery, Queen Square,
London, and the Royal Free Hospital, London,
between January 1999 and August 2005, in order to
identify all cases of pathologically confirmed
vasculitis.
Tissue processing
Nerve biopsies were of the superficial peroneal,
superficial radial or sural nerve; muscle biopsies
were taken from either the vastus lateralis or
peroneus brevis muscles. Following biopsy, part of
the nerve was frozen in liquid nitrogen or
processed into paraffin wax, and another piece
embedded in epoxy resin using standard protocols.
Teased nerve fibre preparations were performed in
selected patients. Paraffin sections were stained
with haematoxylin–eosin and elastic Van Gieson,
as well as a panel of antibodies, including anti-
CD45RO and anti-CD3 (for T lymphocytes) and
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immunocytochemically for B lymphocytes (CD22), T lympho-
cytes (CD4 and CD8), early macrophage marker (CD68) and
late macrophage product (Mac387). Epoxy resin sections were
stained with methylene blue–azure A or thionine and acridine
orange, and areas selected for electron microscopy sectioned at
70 nm and stained with uranyl acetate and lead citrate.
Muscle biopsies were frozen in isopentane cooled with liquid
nitrogen. Cryosections (10 mm) were cut, mounted on cover-
slips and dried at room temperature for 1 h. Sections were
stained with haematoxylin–eosin and Gomori trichrome, as
well as with a routine panel of histochemical stains.
Immunohistochemical staining for CD3, CD8, CD4, CD20
and CD68 was performed using standard methods.
Pathological selection criteria
Nerve biopsies were classified as showing definite or probable
vasculitis. Definite vasculitis was diagnosed if endoneurial or
epineurial vessels showed evidence of vessel wall infarction in
association with perivascular or transmural infiltration by
inflammatory cells. Vessel wall infarction was diagnosed if there
was evidence of destruction and disorganisation of the muscularis
by fibrinoid necrosis, disruption of the endothelium or internal
elastic lamina, thrombosis of the lumen or haemorrhage into the
wall of the vessel. Probable vasculitis was diagnosed if there was
transmural or perivascular inflammation not accompanied by
vessel wall infarction but associated with at least one of the
following: fibrous scarring/intimal proliferation, chronic orga-
nised thrombosis (with/without recanalisation), haemosiderin
Table 1 Characteristics of the vasculitic neuropathy cohort analysed collectively and by vasculitis group
All patients
(n=53)
SVN
(n=31)
NSVN
(n=22)
Clinical
Age (year)* 56 (12.6) 55 (12.4) 59 (12.7)
Sex (Men:Women) 23:30 14:17 9:13
Duration (months)* (median) 14.8 (23.3) (6) 8.5 (8.3) (6) 23.5 (33) (8)
Systemic Sx 33 (62) 28 (90) 5 (23)
Pain 46 (87) 27 (87) 19 (86)
Clinical course P:SW 19:34 9:22 10:12
Neuropathy pattern
ASYSM 24 (45) 15 (48) 9 (41)
ASYS 7 (13) 3 (10) 4 (18)
MM 11 (20) 8 (26) 3 (14)
SYSM 6 (11) 2 (6) 4 (18)
Other bLSP 1, bBRP 1,
M 1, SFN 1,
SYS 1
bLSP 1, M 1,
SYS 1
bBRP 1, SFN 1
CN 4 (8) 2 (6) 2 (9)
Laboratory data
Anaemia 13/53 (25) 12/31 (39) 1/22 (5)
ESR (mm/h)* 39 (36) 52 (36) 23 (27)
ESR .20 mm/h 26/49 (53) 20/28 (71) 6/21 (29)
ANA pos 7/52 (13) 6/30 (20) 1/22 (5)
ANCA pos 10/52 (19) 10/31 (32) 0/21
RF positive 12/50 (24) 10/29 (28) 2/21 (9)
qCSF protein 8/23 (35) 7/13 (54) 1/10 (10)
qCSF white blood cell count 4/23 (17) 3/13 (23) 1/10 (10)
OCB +ve 6/22 (27) 5/12 (42) 1/10 (10)
Nerve pathology
Definite vasculitis 19/53 (36) 15/31 (48) 4/22 (18)
Probable vasculitis 33/53 (62) 16/31 (52) 17/22 (77)
No vasculitis 1/53 (2) 0/31 (0) 1/22 (5)
Wallerian degeneration 45/53 (85) 26/31 (84) 19/22 (86)
Asymmetric nerve fibre loss 17/53 (32) 8/31 (26) 9/22 (41)
Haemosiderin 11/53 (21) 8/31 (26) 3/22 (14)
Fibrous obliteration¡recanalisation 15/53 (28) 11/31 (35) 4/22 (18)
Muscle pathology
Definite vasculitis 3/24 (13) 3/17 (18) 0/7 (0)
Probable vasculitis 8/24 (33) 6/17 (35) 2/7 (29)
No vasculitis 13/24 (54) 8/17 (47) 5/7 (71)
Inflam infiltrate but no frank vasculitis 5/24 (21) 2/17 (12) 3/7 (43)
Myofibre necrosis 5/24 (21) 3/17 (18) 2/7 (29)
Neurogenic change 15/24 (63) 12/17 (71) 3/7 (43)
Data expressed as *mean (SD) or n (%) unless otherwise indicated.
ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; ASYS, asymmetric sensory neuropathy; ASYSM,
asymmetric sensorimotor neuropathy; bBRP, bilateral brachial plexopathy; bLSP, bilateral lumbosacral plexopathy; CN, cranial
nerve involvement; Duration, duration of symptoms prior to biopsy; ESR, erythrocyte sedimentation rate; M, mononeuropathy; MM,
mononeuritis multiplex; NSVN, non-systemic vasculitic neuropathy; OCB+, unmatched oligoclonal bands in cerebrospinal fluid; P,
progressive; RF, rheumatoid factor; SFN, small fibre neuropathy; SVN, systemic vasculitic neuropathy; SW, stepwise; Sx,
symptoms; SYS, symmetrical sensory neuropathy; SYSM, symmetrical sensorimotor neuropathy.
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fibre loss. In muscle biopsy specimens, similar diagnostic criteria
for definite vasculitis were applied. Probable vasculitis was
diagnosed where transmural inflammation was not accompanied
by fibrinoid necrosis of the vessel wall or any of the other vascular
changes described above as representing evidence of definite
vasculitis. Note that in muscle, transmural inflammation alone
without the additional features which were applied to nerve
biopsies was sufficient to diagnose probable vasculitis. This was
because some of these features (prominent Wallerian degenera-
tion or asymmetric nerve fibre loss) can only be applied to nerve
and we felt such a definition would be overly restrictive when
applied to muscle.
Clinical and electrophysiological data
Clinical case notes were reviewed to provide clinical and
electrophysiological data for all patients meeting the patholo-
gical criteria for vasculitis. All patients were clinically suspected
of having vasculitis. The pattern of neuropathy was determined
by the findings on clinical examination. Nerve conduction
studies and electromyography were performed routinely prior to
biopsy, using standard techniques. Neurophysiological exam-
ination was performed in more than one laboratory and by a
number of different neurophysiologists. If the sural nerve
sensory action potential (SAP) was either reduced or absent,
this nerve was biopsied; if not, an alternative affected nerve was
chosen. The one exception to this was a patient with a small
fibre neuropathy with normal neurophysiology and in whom
the sural nerve territory was clinically affected (and therefore
biopsied). In all cases, the biopsied nerve was clinically affected.
All muscle biopsies were taken from the vastus lateralis, apart
from one taken from the PBM.
Patients with pathologically confirmed vasculitis were
divided into SVN and NSVN groups. The criteria that were
used to define cases as NSVN were as follows: (1) no evidence of
involvement outside the peripheral nervous system (except
striated muscle) and (2) no underlying causative agent (hepatitis
B, hepatitis C, HIV, drug exposure, connective tissue disorder,
malignancy or cryoglobulinaemia). Patients with diabetes
mellitus were not excluded. Systemic vasculitis was defined as
in the Chapel Hill Consensus Conference.
10 Constitutional
symptoms such as fever and weight loss and serological tests
such as antinuclear antibodies (ANA), antineutrophil cytoplas-
mic antibodies (ANCA), erythrocyte sedimentation rate (ESR)
and rheumatoid factor (RF) were not in themselves used to
diagnose SVN unless independent clinical criteria for the
diagnosis of a connective tissue disorder were present.
Statistics were performed using SigmaStat 3.5 software.
Categorical variables were analysed using the x
2, Fisher’s exact
test or McNemar’s test where appropriate. The Mann–Whitney
rank sum test was used to compare the duration of symptoms
prior to biopsy in SVN and NSVN cohorts as the data were not
normally distributed.
RESULTS
Clinical features
Fifty-three patients were identified on the basis of a patholo-
gically confirmed diagnosis of vasculitis between January 1999
and August 2005. The clinical characteristics of our cohort of
patients are summarised in table 1 and a breakdown of all
patients is shown in supplementary table 1 (available online).
Thirty-one patients (58%) had SVN and 22 (42%) NSVN. There
was a female preponderance (women:men 30:23). Age range at
the time of biopsy was 32–79 years (mean 56 (SD 13)). Duration
of symptoms prior to biopsy ranged from 1 to 144 months
(mean 15 (SD 23), median 6). Mean duration of symptoms prior
to biopsy was shorter in the SVN than in the NSVN group (8.5
vs 23.5 months, respectively) but this difference was not
statistically significant (Mann–Whitney rank sum test,
p=0.36). The majority (87%) of neuropathies were painful on
presentation and the most common presentation was with
either an asymmetric sensorimotor neuropathy or mononeuritis
multiplex (45% and 20% of patients, respectively). Nine
patients (17%) had only sensory findings on presentation (one
with a pure small fibre neuropathy). One patient presented
with a bilateral asymmetric brachial and another with bilateral
asymmetric lumbosacral plexopathy. Only four patients (8%)
had cranial nerve involvement (third cranial nerve in one
patient, fifth cranial nerve in two patients, and sixth cranial
nerve in one patient). Table 2 shows the frequency of
involvement of different motor nerves, as determined by clinical
examination. Supplemental table 2 (available online) shows the
same data divided into SVN versus NSVN groups. Note that for
the purposes of table 2, the observed deficits were decomposed
into constituent peripheral nerves (sciatic nerve involvement in
two patients was reduced to peroneal and tibial). There was a
distal predominance. The most commonly involved nerve was
the peroneal (86% of patients); in the upper limbs the most
commonly involved nerve was the ulnar (63% of patients).
In the NSVN group, 16% of patients suffered weight loss and
5% had fever. As expected, systemic features were much
commoner in the SVN group (p,0.001, comparing the
proportion of patients with systemic symptoms SVN versus
NSVN; Fisher’s exact test), in which weight loss occurred in
52% and fever in 18%. In the SVN group there were a number of
additional features, including: arthralgia (26%), rash (23%),
renal (19%), respiratory (19%) and gastrointestinal involvement
(16%). The diagnoses of those patients suffering from SVN
included microscopic polyangiitis (n=4 patients), Churg–
Strauss syndrome (n=3), hepatitis B (n=3), polyarteritis
nodosa (n=3), rheumatoid vasculitis (n=3), Wegener’s gran-
ulomatosis (n=3), hepatitis C (n=2), HIV (n=2), paraneo-
plastic secondary to small cell lung cancer (n=2), Sjo ¨gren’s
syndrome (n=2), undifferentiated connective tissue disorder
(n=2), chronic graft versus host disease following bone marrow
allograft for non-Hodgkin’s lymphoma (n=1) and systemic
sclerosis (n=1).
Laboratory findings
Laboratory findings are summarised in table 1. As expected,
patients with SVN compared with those with NSVN were
significantly more likely to be anaemic (p=0.004, Fisher’s exact
test), to have a raised ESR (p=0.01, x
2 test) and to have positive
Table 2 Frequency of motor nerve involvement in those
patients with vasculitic neuropathy who demonstrated a
motor deficit (patients with pure sensory neuropathy were
excluded from the denominator)
Nerve % per patient % per nerve
Musculocutaneous 9 9
Femoral 32 26
Radial 35 30
Tibial 51 40
Median 58 52
Ulnar 63 55
Peroneal 86 76
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A greater proportion of patients with SVN had positive ANA
and RF serology compared with patients with NSVN but these
differences did not reach significance. In one of the patients
with paraneoplastic neuropathy secondary to small cell lung
carcinoma, antineuronal antibodies were tested and found to be
negative. Twenty-three of our total vasculitis cohort had a
lumbar puncture, of which 11 were abnormal (eight had a CSF
protein concentration .0.65 g/dl, six had unmatched oligoclo-
nal bands and four had a raised CSF white cell count).
Neurophysiology
The neurophysiology is summarised in supplementary table 3
(available online). For each individual study, a brief description
of motor and sensory conduction as well as needle electro-
myography is given and the main clinical conclusion of the
examining neurophysiologist is summarised. The most frequent
finding was that of an asymmetric or patchy axonal motor and
sensory peripheral neuropathy (23 patients, 43%). Relatively
infrequent mononeuropathies were identified (four patients,
8%). Some patients were reported to have had a symmetrical or
generalised neuropathy (13 patients, 25%). Occasional border-
line motor slowing was identified (four patients had mixed
features) but rarely in the frankly demyelinating range (less
than 38 m/s in the upper limbs). In all cases of marked motor
slowing there was evidence of significant or severe loss of motor
axons. There were no cases with convincing findings of
demyelination and no cases of partial motor conduction block.
Nine patients (17%) had a principally sensory neuropathy.
Pathological findings
Figure 1 shows selected examples of vasculitis within nerve and
muscle biopsy specimens. From 53 patients there were 50 sural,
three superficial radial and one superficial peroneal nerve biopsy
(note that one patient had two nerve biopsies—a sural followed
by a superficial radial). In 19 patients (36%) the nerve biopsy
demonstrated definite and in 33 patients (62%) probable
vasculitis. In patients with SVN the nerve biopsy was more
likely to show definite (as opposed to probable) vasculitis when
compared with NSVN patients (48% vs 18%, p=0.04, Fisher’s
exact test). Twenty-four patients had a muscle biopsy at the
same time as their nerve biopsy (23 from the vastus lateralis and
one from the PBM). The muscle biopsy demonstrated vasculitis
in 11 cases (46% of all muscle biopsies and 48% of the vastus
lateralis biopsies); three (13%) muscle biopsies showed definite
and eight (33%) probable vasculitis. None of the muscle biopsies
demonstrating probable vasculitis had accompanying signs of
remote vascular injury (fibrous scarring/intimal proliferation,
chronic organised thrombosis with or without recanalisation).
Of those muscle biopsies which did not demonstrate vasculitis,
five showed an inflammatory cell infiltrate. Five muscle biopsies
(21%) showed myofibre necrosis and 15 (63%) showed
neurogenic changes.
There was only one patient (with NSVN) in whom probable
vasculitis was demonstrated in muscle but not in peripheral
nerve. This patient had undergone a sural nerve biopsy 4 years
prior to undergoing combined superficial radial nerve and vastus
lateralis muscle biopsy (in both cases the biopsied nerve
demonstrated evidence of clinical involvement and the relevant
SAP was reduced or absent). Both nerve biopsies showed an
inflammatory cell infiltrate, asymmetric nerve fibre loss and
acute Wallerian degeneration. However, the inflammatory cell
infiltrate was not centred on blood vessels and therefore did not
meet our diagnostic criteria for definite or probable vasculitis. In
the muscle biopsy there was a small focus of perivascular and
intramural inflammation without evidence of fibrinoid necrosis,
which was classified as probable vasculitis. Combined nerve and
muscle biopsy did not significantly increase the proportion of
patients diagnosed with vasculitis compared with nerve biopsy
alone (p=1.00, McNemar’s test). Two patients with SVN had
skin biopsies which showed evidence of vasculitis, and one
patient with Churg–Strauss syndrome had a laparoscopy and an
Figure 1 (A) 4 mm paraffin sections of
sural nerve and (B) 10 mm frozen sections
of muscle from case No 17 and (C, D)
sural nerve from case No 11, stained with
haematoxylin and eosin (A, B, C) or
immunostained for CD45RO (D). In (A) the
epineurial arteriole is occluded, and in (A)
and (C), regions of fibrin deposition are
present in the vessel wall (arrows). In (A),
(B) and (C), mononuclear inflammatory
cells surround the blood vessel, and
immunohistochemistry for the pan T cell
markers CD45RO and CD3 showed that
they were also present within the vessel
wall (D, arrowheads). Scale bar=50 mm
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formation.
DISCUSSION
The demographic features of our vasculitis cohort were similar
to previous studies, showing a female predominance and a
tendency for the condition to affect the elderly.
571 1 – 1 4 In
agreement with previous reports,
3671 51 6we have found that
pain is a prominent symptom described by the vast majority
(87%) of our patients. Most of our patients presented with an
asymmetric neuropathy, usually either an asymmetric sensor-
imotor neuropathy (45%) or mononeuritis multiplex (20%).
Only 11% presented with a symmetrical sensorimotor neuro-
pathy. Reports of the proportion of patients presenting with
symmetrical compared with asymmetric findings in the
literature vary greatly from 2% of patients having a symmetrical
neuropathy in one recent study of NSVN
6 up to 76%
17 in a study
involving patients with SVN and NSVN. These discrepancies
may relate to the extent to which minor asymmetries on
examination are taken into account, or to the different patient
populations. No patient in our cohort had a purely motor
neuropathy although 15% presented with a pure sensory
neuropathy, a proportion similar to previous reports.
6791 21 81 9
Very few of our patients (8%) had cranial nerve involvement.
The most commonly involved nerve in the lower limbs was the
peroneal nerve and in the upper limbs the ulnar nerve. The
frequent involvement of the peroneal nerve is compatible with
experimental evidence demonstrating that the sciatic nerve
bifurcation is a watershed zone, being particularly susceptible to
ischaemia.
20
Peripheral nerve vasculitis can occur either as part of a
multisystem disorder (SVN) or as a disorder restricted to the
peripheral nervous system (NSVN). In our cohort, patients with
SVN had a shorter duration between symptom onset and nerve
biopsy, more systemic symptoms and were more likely to have
anaemia, raised inflammatory markers and positive serology for
ANA, ANCA or RF than patients with NSVN.
It can be difficult to compare published cohorts of peripheral
nerve vasculitis as different definitions of vasculitis have been
used. In this study, we categorised peripheral nerve vasculitis
into definite and probable. In definite vasculitis, there is
evidence of both vascular inflammation as well as recent
damage to the vessel wall. In probable vasculitis, there are
transmural or perivascular inflammatory cells in combination
with other features suggestive of vasculitis, such as prominent
Wallerian degeneration, asymmetric nerve fibre loss or evidence
of previous vascular injury (haemosiderin deposition or fibrous
obliteration with or without recanalisation). A number of
previous series have also subdivided cases into definite and
probable vasculitis
67while some have been more restrictive by
including only those cases in which there is evidence of both
vessel wall inflammation and necrosis.
4 The inclusion of cases in
which the nerve biopsy shows evidence of vessel wall
inflammation without frank necrosis but with other features
suspicious of vasculitis (ie, asymmetric nerve fibre loss,
prominent Wallerian degeneration, predominant axonal
changes) has been shown to increase the estimated sensitivity
of the procedure from 61% to 86% with only a small loss of
specificity.
12
It was first reported in 1988 that combined nerve and muscle
biopsy using superficial peroneal nerve (SPN) and peroneus
brevis muscle (PBM) could increase the diagnostic yield
compared with nerve biopsy alone.
4 Of 83 patients who had
the combined procedure, 37 (45%) had vasculitis in muscle but
not in nerve and, overall, muscle biopsy was diagnostic for
necrotising arteritis in 80% and nerve biopsy in 55% of cases. In
a more recent review, the same authors described a larger cohort
of 425 patients in which vasculitic lesions were found in muscle
only in 28% of patients, nerve only in 45% and both in 31.5% of
patients.
1 A number of other groups
91 22 1describing combined
SPN and PBM biopsy in the diagnosis of vasculitis have also
found a sizeable percentage of patients in whom vasculitis is
present in muscle but not nerve (varying between 9% and 27%).
There are fewer evaluations of diagnostic yield when combining
sural nerve biopsy with muscle biopsy. In 33 patients described
as part of a cohort selected for the presence of muscle vasculitis
(principally gastrocnemius), vasculitis was not found in the
sural nerve in 20% of cases.
13 Claussen et al described a series of
115 combined sural nerve and muscle biopsies (principally
tibialis anterior and gastrocnemius) performed for suspected
vasculitis. Histopathological evidence of vasculitis was found in
39% of cases and in agreement with our own findings,
combined muscle biopsy did not improve diagnostic yield (there
were no cases where vasculitis was demonstrated in muscle but
not in nerve).
22
Our policy is to use neurophysiology to target nerve biopsy
and we preferentially chose the sural nerve. If the sural nerve is
clinically involved and the SAP is reduced or absent, then this
nerve is biopsied. If the sural nerve SAP is normal, an alternative
affected nerve is used. Twenty-four patients had a simultaneous
muscle biopsy (23 from the vastus lateralis and one from the
PBM). In contrast with a number of previous studies, we only
found a small increase in diagnostic yield when performing
combined nerve and muscle biopsy. Only one patient (4% of all
patients with the simultaneous procedure) had evidence of
probable vasculitis present in muscle but not in nerve.
There are potentially a number of reasons why we found only
a small increase in the diagnostic yield from combined nerve and
muscle biopsies in our study. In the vast majority of cases we
have biopsied a proximal muscle (vastus lateralis) while most
other groups have biopsied more distal muscles, such as either
the PBM or gastrocnemius. There could be a distal predomi-
nance for muscle vasculitis. In our series, 46% of the muscle
biopsies from patients with peripheral nerve vasculitis showed
vasculitis. This is much lower than the figure of 80% using PBM
described by Said and colleagues,
4 although two other groups
have found results which vary between 31% and 59%.
91 2 A
second possibility is the physical proximity of the SPN and PBM
versus the remoteness of the sural nerve and vastus lateralis. It
is possible that a contiguous muscle to an affected nerve is more
likely to demonstrate vasculitis than a remote muscle, although
this has not been studied. These differences may relate to the
different nerves being biopsied. The sensitivity of SPN/PBM
biopsy for vasculitis has been estimated at 60–70%
12 18 and the
sensitivity of sural nerve biopsy is given as 50%.
72 3However, it
is difficult to draw conclusions given the different patient
groups and definitions of vasculitis used in these studies. One
study of NSVN patients did compare the sensitivity of SPN/
PBM versus sural nerve biopsy in the diagnosis of definite
vasculitis and found increased sensitivity of 58% versus 47%,
respectively, but this was not statistically significant.
6 A recent
study comparing complications following SPN/PBM versus
sural nerve biopsy has shown that although SPN biopsy can
lead to a greater area of sensory loss compared with sural nerve
biopsy, there is very little difference in other complications.
24
Differences in the published diagnostic yield of combined nerve
and muscle biopsy may also relate to the case mix (eg, the
proportion of SVN versus NSVN cases) and the stringency of
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muscle. The fact that in our two centres only 50% of patients
who had a nerve biopsy for the investigation of vasculitis also
had a combined muscle biopsy does introduce a source of
potential bias into our study.
In conclusion, the practice of combined nerve and muscle
biopsy when peripheral nerve vasculitis is suspected has arisen
because of studies demonstrating the increased diagnostic yield
when SPN and PBM are simultaneously biopsied. Our study
clearly shows that the routine biopsy of the vastus lateralis
simultaneously with a sural nerve biopsy does not significantly
increase the diagnostic yield in cases of suspected peripheral
nerve vasculitis. The crucial next question to be addressed is
whether combined SPN/PBM is truly superior to a sural nerve
biopsy alone when peripheral nerve vasculitis is suspected. The
only way of definitively answering this question would be to
perform a randomised prospective study in patients with
suspected vasculitis who had evidence clinically and neurophy-
siologically of both sural nerve and peroneal nerve involvement.
In addition, it would be important to compare the morbidity of
both procedures. In the meantime, we suggest choosing a nerve
to biopsy that is clinically and neurophysiologically affected.
There is insufficient evidence at present to preferentially suggest
either the sural nerve or combined SPN/PBM biopsy if both
nerves are affected clinically. If the sural nerve is the nerve
chosen to be biopsied to diagnose vasculitis, then it is not
routinely worth doing a vastus lateralis biopsy at the same time.
If the sural nerve biopsy does not demonstrate vasculitis but the
clinical suspicion remains high, then another nerve and/or a
muscle biopsy (eg, SPN/PBM) should be considered.
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